Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
118
Recruiting Now
118
Top Conditions in Phase 2 / Phase 3
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT07155187 Phase 2, Phase 3
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (...
Condition
Non-Small Cell Lung Cancer
Enrollment
490 pts
Location
United States, Australia, Austria
Sponsor
AbbVie
NCT06798363 Phase 2, Phase 3
Recruiting
Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatm...
Condition
Infantile Hemangioma
Enrollment
32 pts
Location
China
Sponsor
West China Hospital
NCT05166343 Phase 2, Phase 3
Recruiting
POHCA Resuscitation: Evaluation of IM Epinephrine
Condition
Pediatric Out-of-Hospital Cardiac Arrest
Enrollment
284 pts
Location
Canada
Sponsor
London Health Sciences Centre
NCT05878717 Phase 2, Phase 3
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosi...
Condition
Systemic Sclerosis Associated Interstitial Lung Disease
Enrollment
300 pts
Location
United States, Argentina, Australia
Sponsor
GlaxoSmithKline
NCT06597474 Phase 2, Phase 3
Recruiting
Food-Body-Mind Intervention (16 Weeks)
Condition
Mental Health Wellness
Enrollment
800 pts
Location
United States
Sponsor
Michigan State University
NCT06328608 Phase 2, Phase 3
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Child...
Condition
Fabry Disease
Enrollment
22 pts
Location
United States, Austria, France
Sponsor
Chiesi Farmaceutici S.p.A.
NCT04782947 Phase 2, Phase 3
Recruiting
Epidural Stimulation and Resistance Training After SCI
Condition
Spinal Cord Injuries
Enrollment
20 pts
Location
United States
Sponsor
United States Department of De
NCT07294508 Phase 2, Phase 3
Recruiting
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positi...
Condition
HER2 + Breast Cancer
Enrollment
706 pts
Location
China
Sponsor
Shanghai Henlius Biotech
NCT03150576 Phase 2, Phase 3
Recruiting
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadj...
Condition
Breast Cancer
Enrollment
780 pts
Location
United Kingdom
Sponsor
Cambridge University Hospitals
NCT07426055 Phase 2, Phase 3
Recruiting
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Stage...
Condition
Prostate Cancer (Adenocarcinoma)
Enrollment
1,000 pts
Location
Poland
Sponsor
Affidea Nu-med Center of Oncol
NCT06721949 Phase 2, Phase 3
Recruiting
Taurine Supplementation in Long COVID
Condition
Long COVID
Enrollment
300 pts
Location
Canada
Sponsor
University of Alberta
NCT07556991 Phase 2, Phase 3
Recruiting
Prospective Clinical Investigation on Infection as a Cause of Chronic Subdural H...
Condition
Chronic Subdural Hematomas
Enrollment
164 pts
Location
Germany
Sponsor
University of Rostock
NCT07214818 Phase 2, Phase 3
Recruiting
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
Condition
Nephrotic Syndrome
Enrollment
75 pts
Location
Egypt
Sponsor
Mansoura University
NCT06365424 Phase 2, Phase 3
Recruiting
Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
Condition
Primary Biliary Cholangitis
Enrollment
117 pts
Location
China
Sponsor
Xijing Hospital of Digestive D
NCT05431088 Phase 2, Phase 3
Recruiting
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
Condition
Sickle Cell Disease
Enrollment
389 pts
Location
United States, Brazil, India
Sponsor
Pfizer
NCT06007846 Phase 2, Phase 3
Recruiting
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Condition
Hepatocellular Carcinoma
Enrollment
12 pts
Location
United States
Sponsor
Inova Health Care Services
NCT07217873 Phase 2, Phase 3
Recruiting
IntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study
Condition
Scoliosis Correction
Enrollment
120 pts
Location
United States
Sponsor
Columbia University
NCT06789783 Phase 2, Phase 3
Recruiting
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment
Condition
Cornelia De Lange Syndrome
Enrollment
34 pts
Location
Italy
Sponsor
University of Milan
NCT06095141 Phase 2, Phase 3
Recruiting
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Defici...
Condition
Pancreatic Adenocarcinoma
Enrollment
30 pts
Location
China
Sponsor
Fudan University
NCT06344169 Phase 2, Phase 3
Recruiting
Dinalbuphine Ester (Naldebain) for Pain Management After Cesarean Section
Condition
Postsurgical Pain
Enrollment
120 pts
Location
Taiwan
Sponsor
Dalin Tzu Chi General Hospital
NCT07163611 Phase 2, Phase 3
Recruiting
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a ...
Condition
Membranous Nephropathy - PLA2R Induced
Enrollment
20 pts
Location
Netherlands
Sponsor
Radboud University Medical Cen
NCT06996561 Phase 2, Phase 3
Recruiting
Exploring the Impact of Genetic Variations on The Clinical Efficacy of Nalbuphin...
Condition
Cholecystectomy
Enrollment
263 pts
Location
Pakistan
Sponsor
Dr. Asma Abdus Salam
NCT07221682 Phase 2, Phase 3
Recruiting
Comparison of Supra vs Infra Inguinal Fascia Iliaca Blocks for Spinal Positionin...
Condition
Post Operative Analgesia
Enrollment
60 pts
Location
Pakistan
Sponsor
Sahiwal medical college sahiwa
NCT07302854 Phase 2, Phase 3
Recruiting
Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator ...
Condition
Acute Ischemic Stroke
Enrollment
382 pts
Location
China
Sponsor
Xiang Luo
NCT06624644 Phase 2, Phase 3
Recruiting
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Mel...
Condition
Melanoma (Skin Cancer)
Enrollment
135 pts
Location
United States
Sponsor
Linnaeus Therapeutics, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology